Celyad Wins First US Patent Covering Allogeneic CAR-T Cells - Quick Facts

(RTTNews) - Belgian biopharmaceutical company Celyad SA (CYAD) announced Friday the issuance of United States Patent No. 9,181,527 relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor or TCR-deficient and express a Chimeric Antigen Receptor or CAR.

The Celyad Allogeneic Patent significantly strengthens Celyad's patent portfolio in the CAR T-Cell field and its leadership in engineered cell therapy.

The company noted that the granted product claims are not limited to specific CARs or specific methods of generating allogeneic CAR T-Cells, such as genome editing or genetic engineering. The patented products are applicable for use in treating various human disease conditions such as cancer, chronic infectious diseases, and autoimmunity.

Christian Homsy, CEO of Celyad, said, "The Company intends to maximize the significant therapeutic potential of our allogeneic CAR-T technology platform, either on our own or potentially through one or more strategic collaborations."

Celyad currently has pre-clinical studies underway to develop allogeneic cancer therapies by using a TCR Inhibitory Molecule, or "TIM", in combination with a next generation CAR construct that incorporates a natural killer receptor.